Trial Profile

Phase II Multi-Centric, Randomised, Open-Label, Parallel-Group Study to Assess the Non-Inferiority of Pamorelin [triptorelin] 11,25mg SC [subcutaneous] Injected Versus Pamorelin 11,25mg IM [intramuscular] Injected in Patients Suffering From Advanced Prostate Cancer

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 Dec 2009 Actual patient number (25) added as reported by ClinicalTrials.gov.
13 Oct 2009 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
26 Jun 2008 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com